Document:

EX-10.44

 Exhibit 10.44 
 SUMMARY OF COMPENSATION ARRANGEMENTS 
 WITH NON-EMPLOYEE DIRECTORS

 (Effective as of December 31, 2012) 
 The following summarizes the compensation and benefits received by the non-employee Directors of CryoLife as of December 31, 2012. It is intended to be a summary of compensation arrangements, and in
no way is intended to provide any additional rights to any non-employee Director. 
 Annual Retainer and Committee Chair Fees 

Each of the non-employee Directors of the Board of Directors of CryoLife receives an annual cash retainer of $40,000. Each committee chair
also receives a fee in addition to the annual cash retainer in the amounts shown in the following table. The committee chair does not receive this fee if the committee chair also serves as the Presiding Director. 

 

					
	 Annual Fees For Committee Chairs
	  	 	 
	 Audit Committee
	  	$	15,000	  
	 Compensation Committee
	  	$	10,000	  
	 Nominating and Corporate Governance Committee
	  	$	7,500	  
	 Regulatory Affairs and Quality Assurance Policy Committee
	  	$	7,500	  

 The Presiding Director receives an additional annual cash retainer of $25,000. CryoLife pays all cash
retainers on a monthly basis. 
 Restricted Stock Grants 
 Non-employee Directors of CryoLife are eligible for equity grants, which are generally made in May of each year. The annual equity portion of non-employee Director compensation for fiscal 2012 was paid in
the form of a grant of 10,000 shares of restricted stock. These shares were issued following the annual meeting of stockholders and vest on the first anniversary of issuance. The size and terms of the annual equity grant are subject to annual
reevaluation by the Compensation Committee. If a Director ceases to serve as a Director as a result of his death or disability or because he has fully served his term but is not standing for re-election, then his award will immediately become fully
vested on the date he ceases to be a Director. If a Director ceases to serve as a Director for any other reason, he will forfeit any unvested portion of the award.EX-10.47

 Exhibit 10.47 
 AMENDED AND RESTATED 
 FISCAL YEAR
         
 BONUS AGREEMENT 

UNDER THE 

2007 EXECUTIVE INCENTIVE PLAN 
 This AMENDED AND RESTATED CRYOLIFE, INC. FISCAL YEAR          EXECUTIVE INCENTIVE PLAN BONUS AGREEMENT (this “Agreement”) was adopted
by the Plan Committee pursuant to the CryoLife, Inc. (the “Company”) 2007 Executive Incentive Plan (the “Plan”) (a copy of which is attached as Exhibit 1) and agreed to by the Company and
                     (“Executive”) effective             ,
        . This Agreement is effective for the fiscal year ending December 31,          (the “Plan Year”). Capitalized terms used but not
otherwise defined herein shall have the meanings given them in the Plan. 
 1. Calculation of Bonus.
Subject to the further adjustments, limitations and additions provided for in the Plan and this Agreement, Executive’s bonus for the          fiscal year shall be computed as set forth on Exhibit
2 attached hereto. 
 2. Term of Agreement. This Agreement shall be effective only for the Plan
Year (i.e., the fiscal year ending December 31,         ). 
 3. No
Employment Arrangement Implied. Nothing in this Agreement or the Plan shall imply any right of Employment for Executive, and except as set forth in Section 10 of the Plan with respect to a Change of Control or as otherwise
determined by the Committee, in its discretion, or contained in any other agreement between Executive and the Company, which shall not be affected hereby, if Executive is terminated, voluntarily or involuntarily, with or without cause, prior to the
end of the Plan Year, Executive shall not be entitled to any bonus for the Plan Year regardless of whether or not such bonus had been or would have been earned in whole or in part, but any unpaid bonus earned with respect to a prior fiscal year
shall not be affected. 
 4. Plan Provisions shall Govern. This Agreement is subject to and governed by the Plan
and in the case of any conflict between the terms of this Agreement and the contents of the Plan, the terms of the Plan will control. 
 5. Governing Law. The interpretation, construction and performance of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State
of Georgia without regard to the principle of conflict of laws. 
 6. Counterparts. This Agreement may be executed
in counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument. 
 7. Severability. Provided the other provisions of this Agreement do not frustrate the purpose and intent of the law, in the event that any portion of this Agreement shall be determined to be
invalid or unenforceable to any extent, the same shall to that extent be deemed severable from this Agreement, and the invalidity or unenforceability thereof shall not affect the validity and enforceability of the remaining portion of this
Agreement. 
 8. Amendment and Termination. The Company may amend this Agreement, at any time prior to the payment
of the bonus, without the approval of Executive. Notwithstanding anything to the contrary contained in this Agreement, the Company may terminate this Agreement at any time prior to the payment of the bonus and Executive shall not be entitled to any
bonus under this Agreement for the Plan Year regardless of when this Agreement is terminated. 

  
 1 

 IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by a duly
authorized officer of the Company and Executive has executed this Agreement as of the day and year first written above. 
  

							
	CRYOLIFE, INC.	 		 	EXECUTIVE
				
	By:	 	  
	 		 	  

				
	Title:	 	  
	 		 	  

  
 2 

 EXHIBIT 1 

“PLAN” 

  
 3 

 EXHIBIT 2 

 
  
 Executive may earn an additional percentage of Executive’s base salary based on three components: (i) the Company attaining specified adjusted revenue targets; (ii) the Company attaining
specified adjusted net income targets and (iii) the Executive’s personal performance review. Executive’s target bonus of     % is based on the achievement of     % of target in each of the three
components (    % for Adjusted Revenues,     % for Adjusted Net Income,     % for Personal Performance). 
 No bonus is payable in a given category if the specified minimum set forth below in that category is not obtained. Subject to the provisions of the Plan and the discretion of the Committee, all bonuses
will be paid in cash. Details regarding bonus calculation are set forth below, with the     % target level bolded for ease of reference (data points shown in the tables, other than the minimum and maximum levels, are
representative only, and a pro rata portion of the bonus shall be earned for performance achieved that falls between the data points shown): 
  

																																													
	 Adjusted Revenues*
	 
	 Adjusted Revenue* Target (in thousands)
	 	$
  
 
	            
 Minimum
Level
	  
   
  
	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  
	 Bonus Payable
	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  

  

	*	Adjusted Revenues are fiscal      Company revenues from (i) cardiac and vascular allograft tissue processing, (ii) BioGlue, BioFoam and
related product sales, (iii) PerClot sales and (iv) Cardiogenesis sales. 

	**	There is no maximum level for adjusted revenues. Achievement of adjusted revenues above this level will result in bonus payments on a sliding scale consistent with
the above payment ratios. 

  
 4 

																																													
	 Adjusted Net Income*
	 
	 Adjusted Net Income* Target (in thousands)
	 	$
  
 
	            
 Minimum
Level
	  
   
  
	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  
	 Bonus Payable
	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  	 	$	            	  

  

	*	Adjusted Net Income is GAAP net income for     , exclusive of interest expense, interest income, stock compensation expense (other than stock
compensation expense related to the bonus plan), R&D expense (excluding salaries and related expenses), other income and expense, income taxes, grant revenue, charges related to acquisitions/license/business development/integration, and
litigation costs. 

	**	There is no maximum level for adjusted net income. Achievement of adjusted net income above this level will result in bonus payments on a sliding scale consistent
with the above payment ratios. 

  

									
	 Personal Performance
	 
	 Personal Performance Rating
	  	Does Not
Meet	 	  	Meets or
Exceeds	 
	 Bonus Payable
	  	$	0	  	  	$	            	  

  
 5EX-4.1

 Exhibit 4.1 

 
 

 
 C0000000230 | M 104598 Number 00000000 Shares * * * * 0 * * *
* * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * * * * * * * * * * 0 * * * * * sophiris A BRITISH COLUMBIA COMPANY THIS CERTIFIES THAT
**SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SO
PHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIM
EN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*B
IO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q
10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.z ero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC. SPECIMEN
zero****SPECIMEN83578Q10000000 000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****S
PECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHI
RIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN8
3578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*
INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q10000000000SOPHIRIS*BIO*INC.zero****SPECIMEN83578Q100 CUSIP 83578Q100 ISIN CA83578Q1000 IS THE REGISTERED HOLDER OF
**083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero**
**083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero**
**083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero**
**083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero** **083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC. * * * 0 * * *
zero****083578Q10000000000SOPHIRIS*BIO*INC.zero** **083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero**
**083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero**
**083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero**
**083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero**
**083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero****083578Q10000000000SOPHIRIS*BIO*INC.zero** SEE REVERSE FOR CERTAIN DEFINITIONS FULLY PAID AND NON-ASSESSABLE COMMON SHARES WITHOUT PAR VALUE IN THE CAPITAL OF
SOPHIRIS BIO INC. in the Authorized share structure of the above named Company subject to the Articles of the Company transferable on the Central Securities Register of the Company by the registered holder in person or by attorney duly authorized in
writing upon surrender of this certificate properly endorsed. This certificate is not valid unless countersigned by the Transfer Agent and Registrar of the Company. IN WITNESS WHEREOF the Company has caused this certificate to be signed on its
behalf by the facsimile signatures of its duly authorized officers, at Vancouver, British Columbia. President and Chief Executive Officer Dated: Feb 01, 2013 COUNTERSIGNED AND REGISTERED COMPUTERSHARE TRUST COMPANY, N.A. (GOLDEN CO) TRANSFER AGENT
AND REGISTRAR OR COUNTERSIGNED AND REGISTERED COMPUTERSHARE TRUST COMPANY OF CANADA (VANCOUVER) (TORONTO) TRANSFER AGENT AND REGISTRAR Chief Financial Officer By _____________________________ Authorized Officer By ____________________________
Authorized Officer The shares represented by this certificate are transferable at the offices of Computershare Trust Company of Canada in Vancouver, BC; Toronto, ON and Computershare Trust Company, N.A. in Golden, CO. 

 

 
 VOIDThe following abbreviations shall be construed as though the words set forth below
opposite each abbreviation were written out in full where such abbreviation appears: TEN COM - as tenants in common (Name) CUST (Name) UNIF - (Name) as Custodian for (Name) under the TEN ENT - as tenants by the entireties GIFT MIN ACT (State)
(State) Uniform Gifts to Minors Act JT TEN - as joint tenants with rights of survivorship and not as tenants in common Additional abbreviations may also be used though not in the above list. For value received the undersigned hereby sells, assigns
and transfers unto Insert name and address of transferee shares represented by this certificate and does hereby irrevocably constitute and appoint the attorney of the undersigned to transfer the said shares on the books of the Company with full
power of substitution in the premises. DATED: Signature of Shareholder Signature of Guarantor Signature Guarantee: The signature on this assignment must correspond with the name as written upon the face of the certificate(s), in every particular,
without alteration or enlargement, or any change whatsoever and must be guaranteed by a major Canadian Schedule I chartered bank or a member of an acceptable Medallion Signature Guarantee Program (STAMP, SEMP, MSP). The Guarantor must affix a stamp
bearing the actual words “Signature Guaranteed”. In the USA, signature guarantees must be done by members of a “Medallion Signature Guarantee Program” only. Signature guarantees are not accepted from Treasury Branches, Credit
Unions or Caisses Populaires unless they are members of the Stamp Medallion Program. SECURITY INSTRUCTIONS - INSTRUCTIONS DE SECURITE THIS IS WATERMARKED PAPER, DO NOT ACCEP1 WIIMOUT NOTING WAIEHMARK HOLD TO LIGHT TO VERIFY WATERMARK PAPII R
IIIIGHANI , Nl PAS ACCEPTER SANS VERIFIER IA PRESENCE DU FILIGRANE, POUR CE FAIRE, PLACER A LA LUMIERE. EN_COMP_V2_Q1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]